Form 4: uniQure Director Sells Shares to Cover Tax Obligations

Robert Gut, a Director at uniQure N.V., sold 3,336 ordinary shares at a weighted average price of $14.45 to cover estimated withholding taxes upon the vesting of restricted share units.

Summary

• Robert Gut, a Director of uniQure N.V. (QURE), reported a sale of 3,336 ordinary shares.
• The transaction occurred on June 20, 2025.
• The shares were sold at a weighted average price of $14.45, with prices ranging from $14.40 to $14.50 per share.
• This sale was non-discretionary, executed solely to cover estimated withholding taxes upon the vesting of restricted share units.
• Following this transaction, Mr. Gut beneficially owns 56,879 ordinary shares directly.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary sale for tax purposes, not indicative of positive or negative sentiment regarding the company's performance or outlook.

Positives

• The sale was non-discretionary, indicating it was not a signal of a lack of confidence in the company by the director.

Future Outlook

The document does not provide any forward-looking statements or guidance.

Management Comments

• The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement.
• The sale was not a discretionary trade by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common in the biotechnology or pharmaceutical industry where executive compensation often includes equity awards like restricted share units. Such tax-related sales are standard practice and generally do not reflect a change in the company's fundamental outlook or the insider's confidence.

Comparison to Industry Standards

• This type of non-discretionary sale to cover tax obligations upon RSU vesting is a standard practice across publicly traded companies, particularly in industries where equity compensation is prevalent.
• It aligns with common corporate governance and compensation structures seen in biotech and other high-growth sectors.
• No specific comparable companies or projects are mentioned in the document to allow for a direct comparison of results.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related transaction and is unlikely to significantly impact shareholder perception or the company's stock price, as it does not signal a change in the director's confidence.
• Employees: No direct impact on employees is indicated.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to the Issuer, any shareholder, or the SEC staff.

Key Dates

Recommendation

Keywords

uniQure N.V., QURE, Form 4, Insider Trading, Beneficial Ownership, Robert Gut, Director, Share Sale, Restricted Share Units, Tax Withholding